Search results
Results from the WOW.Com Content Network
Temsirolimus is a specific inhibitor of mTOR and interferes with the synthesis of proteins that regulate proliferation, growth, and survival of tumor cells. Though temsirolimus shows activity on its own, it is also known to be converted to sirolimus (rapamycin) in vivo; [4] therefore, its activity may be more attributed to its metabolite rather than the prodrug itself (despite claims to the ...
The scheme is one of a number developed by Biodiversity Information Standards particularly aimed at taxonomic databases. [2] The starting point was the "need for an agreed system of geographical units at approximately 'country' level and upwards for use in recording plant distributions". [1]
The following other wikis use this file: Usage on ar.wikipedia.org تيمزيروليموس; Usage on fa.wikipedia.org تمسیرولیموس; Usage on ja.wikipedia.org
mTOR inhibitors are a class of drugs used to treat several human diseases, including cancer, autoimmune diseases, and neurodegeneration. They function by inhibiting the mammalian target of rapamycin (mTOR) (also known as the mechanistic target of rapamycin), which is a serine/threonine-specific protein kinase that belongs to the family of phosphatidylinositol-3 kinase (PI3K) related kinases ...
The World Flora Online (WFO) is an open-access database, launched in October 2012 as a follow-up project to The Plant List, with the aim of publishing an online flora of all known plants by 2020. [1] It is a project of the United Nations Convention on Biological Diversity , with goal of halting the loss of plant species worldwide by 2020.
This file contains additional information, probably added from the digital camera or scanner used to create or digitize it. If the file has been modified from its original state, some details may not fully reflect the modified file.
Main page; Contents; Current events; Random article; About Wikipedia; Contact us
NHS England has been criticised for delays in deciding on a policy for the prescription of everolimus in the treatment of Tuberous Sclerosis. 20 doctors addressed a letter to the board in support of the charity Tuberous Sclerosis Association saying " around 32 patients with critical need, whose doctors believe everolimus treatment is their best or only option, have no hope of access to funding.